Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

Jeffrey A. Allen; Deborah F. Gelinas; Miriam Freimer; M. Chris Runken; Gil I. Wolfe

doi:10.1016/j.jns.2019.116497

Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

Jeffrey A. Allen, Deborah F. Gelinas, Miriam Freimer, M. Chris Runken, Gil I. Wolfe

Neurology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.

Original language	English (US)
Article number	116497
Journal	Journal of the Neurological Sciences
Volume	408
DOIs	https://doi.org/10.1016/j.jns.2019.116497
State	Published - Jan 15 2020

Bibliographical note

Funding Information:
Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring.

Funding Information:
Dr. Allen is a consultant for Argenyx, CSL Behring, Biotest, Akcea. Dr. Freimer is on advisory boards for ARGENX, Alexion, CSL Behring; research Funding: Argenx, UCB, Ra, Alexion, Catalyst,Grifols, Acceleron,Momenta, Octapharma, Orphazyme, Alnylum, Amicus. Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring . Drs. Gelinas and Runken are employees of Grifols SSNA. Preparation of this manuscript was funded by Grifols (Research Triangle Park, NC), a manufacturer of SCIG and IVIG.

Publisher Copyright:
© 2019 The Authors

Keywords

Chronic inflammatory demyelinating polyneuropathy
Intravenous immunoglobulin
Maintenance therapy
Route of administration comparison
Subcutaneous immunoglobulin

PubMed: MeSH publication types

Journal Article
Review

Publisher link

10.1016/j.jns.2019.116497

Find It

Find It at U of M Libraries

Cite this

@article{627a5faf15e4450b878a68b120af2b2c,

title = "Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?",

abstract = "Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.",

keywords = "Chronic inflammatory demyelinating polyneuropathy, Intravenous immunoglobulin, Maintenance therapy, Route of administration comparison, Subcutaneous immunoglobulin",

author = "Allen, {Jeffrey A.} and Gelinas, {Deborah F.} and Miriam Freimer and Runken, {M. Chris} and Wolfe, {Gil I.}",

note = "Funding Information: Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring. Funding Information: Dr. Allen is a consultant for Argenyx, CSL Behring, Biotest, Akcea. Dr. Freimer is on advisory boards for ARGENX, Alexion, CSL Behring; research Funding: Argenx, UCB, Ra, Alexion, Catalyst,Grifols, Acceleron,Momenta, Octapharma, Orphazyme, Alnylum, Amicus. Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring . Drs. Gelinas and Runken are employees of Grifols SSNA. Preparation of this manuscript was funded by Grifols (Research Triangle Park, NC), a manufacturer of SCIG and IVIG. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2020",

month = jan,

day = "15",

doi = "10.1016/j.jns.2019.116497",

language = "English (US)",

volume = "408",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Immunoglobulin administration for the treatment of CIDP

T2 - IVIG or SCIG?

AU - Allen, Jeffrey A.

AU - Gelinas, Deborah F.

AU - Freimer, Miriam

AU - Runken, M. Chris

AU - Wolfe, Gil I.

N1 - Funding Information: Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring. Funding Information: Dr. Allen is a consultant for Argenyx, CSL Behring, Biotest, Akcea. Dr. Freimer is on advisory boards for ARGENX, Alexion, CSL Behring; research Funding: Argenx, UCB, Ra, Alexion, Catalyst,Grifols, Acceleron,Momenta, Octapharma, Orphazyme, Alnylum, Amicus. Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring . Drs. Gelinas and Runken are employees of Grifols SSNA. Preparation of this manuscript was funded by Grifols (Research Triangle Park, NC), a manufacturer of SCIG and IVIG. Publisher Copyright: © 2019 The Authors

PY - 2020/1/15

Y1 - 2020/1/15

N2 - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.

AB - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.

KW - Chronic inflammatory demyelinating polyneuropathy

KW - Intravenous immunoglobulin

KW - Maintenance therapy

KW - Route of administration comparison

KW - Subcutaneous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=85075263178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075263178&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.116497

DO - 10.1016/j.jns.2019.116497

M3 - Article

C2 - 31765922

AN - SCOPUS:85075263178

VL - 408

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

M1 - 116497

ER -

Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this